Mood - Treatment Resistant Depression - Major Depressive Disorder with inadequate response to 2 or more antidepressants

Areas of Interest:

• Major Depressive Disorder (MDD) journey to Treatment Resistant Depression (TRD)
• TRD: early patient identification & treatment initiation
• Primary care provider’s role in the early identification & treatment of TRD
• Mechanistic rationale to pharmacological treatment approaches
• Algorithmic treatment approaches in TRD including interventional psychiatry treatments
• Early use of new antidepressants in TRD
• Strategies for preventing relapse in TRD, and the impact of relapse prevention
• Value of innovative treatments from the patient & societal perspective
• Impact MDD & TRD in minoritized communities and populations

Mood – Targeting Novel Pathways In Depression

Areas of Interest:

• Clinical correlates between unresolved, residual symptoms of Major Depressive Disorder (MDD) and underlying pathophysiology not addressed with current Standard of Care treatments
• Early use of adjunctive strategies in the treatment of MDD in specialty and primary care setting
• The role of Nurse Practitioners, Physician Assistants and Primary Care providers in assessment, diagnosis and management of MDD
• Clinical and biological underpinnings of anhedonia in MDD
• The neurobiology and neurocircuitry of motivation and reward
• Best practices in the assessment and diagnosis of anhedonia in MDD patients
• Clinical and neurobiological underpinnings of insomnia in MDD
• The role of orexin system in depression
• Clinical, humanistic and economic impact of anhedonia and/or insomnia symptoms in patients with MDD
• Diversity, Equity and Inclusion considerations in assessment, diagnosis and management of MDD (including specific symptoms of anhedonia and/or insomnia)
• Experience of MDD with anhedonia or insomnia by diverse patient segments

Schizophrenia - Adults with Schizophrenia

Areas of Interest:

• Earlier adoption of long-acting injectable antipsychotics (LAI)
• Clinical stability & persistency through advancing patients to a longer dosing interval
• Switching oral antipsychotics to long-acting injectable antipsychotics
• Effects and dynamics of a therapeutic alliance between the treatment team (incl nurse practitioners & pharmacists) and patient/caregiver to co-create a treatment plan early in the patient journey helping patients progress through their treatment plan
• Patient & caregiver preferences in LAI utilization
• Patterns of antipsychotic LAI utilization in minoritized communities and populations (including social determinants of health)
• Competency models assessing injection techniques in the administration of atypical antipsychotic LAIs
• Antipsychotic LAI transition of care models (inpatient to outpatient)
• Champion the destigmatization of schizophrenia to encourage compassion and acceptance

Learners of Interest

• Nurse Practitioners
• Early-in-Career
• Psychiatrists
• Primary Care
• Patient
• Caregiver / Care Team
• Physician Assistants
• Pharmacists
• Payer
• Advocacy Partners

Certificate Of Separation

Please click here to view the certificate of separation
Click here to submit an Independent Medical Education Grant